文献速递白血病淋巴瘤

维奈克拉治疗伴17p缺失的慢性淋巴细胞白血病:II期关键试验全人群结果

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
PubMed 文献 · J Clin Oncol · 2018-05-01

该II期关键试验纳入158例复发/难治或未经治疗(n=5)的del(17p)慢性淋巴细胞白血病患者,接受维奈克拉400 mg每日一次(初始剂量递增)。研究者评估客观缓解率为77%(122/158,完全缓解20%),24个月无进展生存率估计为54%(95%CI 45%-62%),48例(30%)患者血中微小残留病低于10^-4。维奈克拉在该高危人群中获得持久缓解且耐受性良好。

要点

  • 全人群客观缓解率77%(122/158),完全缓解20%,24个月无进展生存率54%(95%CI 45%-62%)。
  • 48例(30%)患者血中微小残留病低于10^-4。
  • 常见3-4级不良事件为血液学事件,经支持治疗和/或剂量调整管理。

核心结论

  • 维奈克拉在del(17p)慢性淋巴细胞白血病患者中取得持久缓解且耐受性良好,该高危人群血中微小残留病低于10^-4的比例较高。

研究设计与样本

  • II期关键试验全人群分析,共纳入158例复发/难治或未经治疗(n=5)的del(17p)慢性淋巴细胞白血病患者,接受维奈克拉400 mg每日一次(初始剂量递增)。

主要发现

  • 患者既往治疗中位数为2线(范围0-10线),71%有TP53突变,48%有≥5 cm的淋巴结。
  • 维奈克拉治疗中位时间为23.1个月(范围0-44.2个月),研究中位时间为26.6个月(范围0-44.2个月)。
  • 全人群研究者评估客观缓解率为77%(122/158),完全缓解20%,24个月无进展生存率估计为54%(95%CI 45%-62%)。
  • 16例既往接受过激酶抑制剂的患者客观缓解率为63%(10/16),24个月无进展生存率估计为50%(95%CI 25%-71%)。
  • 意向性治疗分析中,48例(30%)患者血中微小残留病低于10^-4。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration and European Medicines Agency approval for patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia [del(17p) CLL] was based on results from 107 patients. An additional 51 patients were enrolled in a safety expansion cohort. Extended analysis of all enrolled patients, including the effect of minimal residual disease (MRD) negativity on outcome, is now reported. Patients and Methods Overall, 158 patients with relapsed/refractory or previously untreated (n = 5) del(17p) CLL received venetoclax 400 mg per day after an initial dose ramp up. Responses were based on 2008 International Workshop on Chronic Lymphocytic Leukemia criteria, with monthly physical exams and blood counts. Computed tomography scan was mandatory at week 36, after which assessment made was by clinical evaluation. Marrow biopsy was performed when complete remission was suspected. MRD was assessed by flow cytometry. Results Patients had a median of two prior therapies (range, zero to 10 therapies), 71% had TP53 mutation, and 48% had nodes that were ≥ 5 cm. Median time on venetoclax was 23.1 months (range, 0 to 44.2 months) and median time on study was 26.6 months (range, 0 to 44.2 months). For all patients, investigator-assessed objective response rate was 77% (122 of 158 patients; 20% complete remission) and estimated progression-free survival at 24 months was 54% (95% CI, 45% to 62%). For 16 patients who received prior kinase inhibitors, objective response rate was 63% (10 of 16 patients) and 24-month progression-free survival estimate was 50% (95% CI, 25% to 71%). By intent-to-treat analysis, 48 (30%) of 158 patients achieved MRD below the cutoff of 10-4 in blood. Common grade 3 and 4 adverse events were hematologic and managed with supportive care and/or dose adjustments. Conclusion Venetoclax achieves durable responses and was well tolerated in patients with del(17p) CLL. A high rate of blood MRD < 10-4 was achieved in this high-risk population.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018. PMID: 29715056. doi:10.1200/JCO.2017.76.6840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。